Overview

A Study of GensSci098 in Subjects With Graves' Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-19
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Phase:
PHASE1
Details
Lead Sponsor:
Changchun GeneScience Pharmaceutical Co., Ltd.